Pfizer Past Earnings Performance

Past criteria checks 0/6

Pfizer has been growing earnings at an average annual rate of 9.9%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 13.5% per year.

Key information


Earnings growth rate


EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate13.5%
Return on equity-0.3%
Net Margin-0.5%
Next Earnings Update30 Jul 2024

Recent past performance updates

Recent updates

Pfizer: Seriously Undervalued At Peak Pessimism

Jun 23

Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon

Jun 13

Does Pfizer (NYSE:PFE) Have A Healthy Balance Sheet?

Jun 09
Does Pfizer (NYSE:PFE) Have A Healthy Balance Sheet?

Pfizer: Too Early For A Turnaround

Jun 06

Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs

May 21

Pfizer's Bottom May Be Here - Its Rich Yield Is Tempting

May 12

Pfizer: Ignore The Dead Cat Bounce

May 06

Pfizer Inc.'s (NYSE:PFE) Price Is Out Of Tune With Revenues

May 03
Pfizer Inc.'s (NYSE:PFE) Price Is Out Of Tune With Revenues

Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1?

Apr 29

Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth

Apr 19

Pfizer: The Market Is Wrong

Apr 11

Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns

Mar 18

Pfizer: A Strong Buy Trading Below A 10 P/E Ratio

Mar 08

Pfizer: A Value Trap, Not A Bargain

Feb 28

Pfizer: Turnaround Is Gaining Momentum

Feb 21

Is Pfizer (NYSE:PFE) A Risky Investment?

Feb 21
Is Pfizer (NYSE:PFE) A Risky Investment?

Pfizer Is A Great Investment Over The Next Decade; Buy

Feb 09

Revenue & Expenses Breakdown

How Pfizer makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:PFE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2454,889-28813,90810,665
31 Dec 2358,4962,13413,83610,679
01 Oct 2368,74110,46913,57311,420
02 Jul 2378,14721,49413,40011,435
02 Apr 2393,15429,03513,25811,621
31 Dec 22100,33031,36612,20011,428
02 Oct 2299,87829,95311,32511,260
03 Jul 22101,27529,48110,03211,243
03 Apr 2292,43325,4109,40010,667
31 Dec 2181,28822,4139,56210,360
03 Oct 2168,87719,4859,7149,972
04 Jul 2155,11912,23611,6769,589
04 Apr 2146,0849,03211,4549,184
31 Dec 2041,6516,63011,4188,709
27 Sep 2032,33421211,0068,084
28 Jun 2034,7376,97710,5657,727
29 Mar 2038,1379,42711,6377,716
31 Dec 1940,90510,70712,7667,721
29 Sep 1953,03916,21113,7557,891
30 Jun 1953,65612,63814,0507,948
31 Mar 1953,85911,46414,0047,914
31 Dec 1840,8253,82412,1497,713
30 Sep 1853,37323,80814,4817,827
01 Jul 1853,24422,54514,4927,686
01 Apr 1852,67321,74614,5097,673
31 Dec 1752,54621,30514,6067,645
01 Oct 1752,4719,79114,5467,843
02 Jul 1752,3478,30814,6087,861
02 Apr 1752,5987,28114,9597,826
31 Dec 1652,8247,19814,8947,858
02 Oct 1653,2436,27014,9567,652
03 Jul 1652,2867,03614,6977,797
03 Apr 1650,9927,61514,3397,787
31 Dec 1548,8516,94814,3257,646
27 Sep 1547,9228,36613,6407,366
28 Jun 1548,1968,91313,6667,135
29 Mar 1549,1169,20013,7767,118
31 Dec 1449,6059,08513,7207,150
28 Sep 1450,04510,46113,8946,902
29 Jun 1450,32710,37013,9446,740
30 Mar 1450,52710,99414,0096,546
31 Dec 1351,58411,33914,1646,551
29 Sep 1351,91710,18514,3456,398
30 Jun 1352,22710,59014,4366,612

Quality Earnings: PFE is currently unprofitable.

Growing Profit Margin: PFE is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PFE is unprofitable, but has reduced losses over the past 5 years at a rate of 9.9% per year.

Accelerating Growth: Unable to compare PFE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PFE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).

Return on Equity

High ROE: PFE has a negative Return on Equity (-0.27%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.